GO-COLITIS Trial in Ulcerative Colitis Patients Shows Simponi Induces Positive Clinical Response

GO-COLITIS Trial in Ulcerative Colitis Patients Shows Simponi Induces Positive Clinical Response
Janssen Pharmaceutical’s Simponi (golimumab) induced a clinical response in more than two-thirds of patients with moderate to severe ulcerative colitis in the induction phase of the GO-COLITIS clinical trial, according to the study “Efficacy and safety of golimumab induction 
for moderate-to-severe ulcerative colitis in 
the United Kingdom: results from the 
GO-COLITIS study (DOP049),” recently presented at the European

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *